<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Catatonia: Treatment and prognosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Catatonia: Treatment and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Catatonia: Treatment and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">M Justin Coffey, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter P Roy-Byrne, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen Marder, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 12, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H6714227"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Catatonia is a behavioral syndrome marked by an inability to move normally despite full physical capacity to do so. The syndrome occurs in the context of many psychiatric and general medical disorders [<a href="#rid1">1</a>]. Prompt treatment of catatonia with benzodiazepines or electroconvulsive therapy (ECT), as well as treatment of the underlying cause, generally leads to remission of catatonia. However, failure to recognize and properly treat catatonia can lead to poor outcomes; malignant catatonia in particular can be fatal.</p><p>This topic reviews the treatment and prognosis of catatonia. The epidemiology, clinical features, assessment, underlying disorders, diagnosis, and differential diagnosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14683.html" rel="external">"Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="headingAnchor" id="H10661798"><span class="h1">DEFINITION OF CATATONIA</span><span class="headingEndMark"> — </span>Catatonia is a behavioral syndrome marked by an inability to move normally, and can occur in patients with underlying psychiatric (eg, autism spectrum disorder, bipolar disorders, psychotic disorders, and unipolar major depression) and general medical disorders. The syndrome is marked by heterogeneous signs that are observed or elicited  (<a class="graphic graphic_table graphicRef53391" href="/z/d/graphic/53391.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef66229" href="/z/d/graphic/66229.html" rel="external">table 2</a>); the most common are immobility, rigidity, mutism, posturing, excessive motor activity, stupor, negativism, staring, and echolalia [<a href="#rid1">1-3</a>].</p><p>Subtypes of catatonia are based upon the specific nature of the movement disturbance and other associated features [<a href="#rid1">1</a>]. The three principal forms in order of incidence are:</p><p class="bulletIndent1"><span class="glyph">●</span>Retarded – Mutism, inhibited movement, posturing, rigidity, negativism, and staring</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Excited – Excessive and purposeless motor activity, restlessness, stereotypy, impulsivity, frenzy, agitation, and combativeness</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignant – Fever, autonomic instability (labile or elevated blood pressure, tachycardia, tachypnea, and diaphoresis), delirium, and rigidity</p><p></p><p>Additional information about the clinical features, subtypes, assessment, underlying disorders, diagnosis, and differential diagnosis of catatonia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14683.html" rel="external">"Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="headingAnchor" id="H87533411"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H85682923"><span class="h2">Setting and management</span><span class="headingEndMark"> — </span>The presence of catatonia reflects that the patient is severely ill with an underlying psychiatric or general medical disorder [<a href="#rid4">4,5</a>]. Patients are commonly hospitalized to treat the catatonic syndrome and underlying disorder, as well as to prevent and manage complications of catatonia such as aspiration pneumonia, venous thromboembolism (deep vein thrombosis and pulmonary embolism), constipation with impaction, and urinary retention [<a href="#rid2">2</a>].</p><p>Malignant catatonia in particular is life-threatening and generally warrants admission to an intensive care unit to monitor and treat [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthermia – Management of hyperthermia requires ensuring adequate airway protection, breathing, and circulation; initiation of rapid cooling; and treatment of complications. (See  <a class="medical medical_review" href="/z/d/html/176.html" rel="external">"Severe nonexertional hyperthermia (classic heat stroke) in adults", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension – Oral or parenteral medication may be necessary for severe hypertension. (See  <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">"Drugs used for the treatment of hypertensive emergencies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiopulmonary instability – Arrhythmias may occur from electrolyte imbalance.</p><p></p><p>For all patients with catatonia, clinicians should try to prevent and manage [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Dehydration and malnutrition – Patients who refuse to eat or drink should be monitored for input and output and may require enteral or parenteral fluids and feeding. (See  <a class="medical medical_review" href="/z/d/html/1617.html" rel="external">"Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Deep vein thrombosis and pulmonary embolism – Deep vein thrombosis may occur in more than 25 percent of patients with catatonia; the retarded subtype of catatonia presents the highest risk [<a href="#rid8">8</a>]. Prevention and treatment of venous thromboembolism includes graduated compression stockings, intermittent pneumatic compression, and anticoagulants. (See  <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Contractures – Studies of patients with structural neurologic damage suggest that stretching and passive range of motion may prevent and treat contractures, but the results are inconsistent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pressure ulcers – Pressure relief is the most important factor in preventing pressure (decubitus) ulcers and can be accomplished with proper patient positioning and appropriate use of pressure-reducing devices. Positioning of bed-bound individuals includes a regular turning and repositioning schedule (eg, every two hours), with attention to vulnerable tissue covering bony prominences such as the sacrum. (See  <a class="medical medical_review" href="/z/d/html/2884.html" rel="external">"Epidemiology, pathogenesis, and risk assessment of pressure-induced skin and soft tissue injury"</a> and  <a class="medical medical_review" href="/z/d/html/2885.html" rel="external">"Prevention of pressure-induced skin and soft tissue injury"</a> and  <a class="medical medical_review" href="/z/d/html/2887.html" rel="external">"Clinical staging and general management of pressure-induced skin and soft tissue injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Excitement and impulsivity – Catatonic excitement and impulsivity are most safely treated with a benzodiazepine such as <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>, although seclusion and physical restraints are occasionally required as well. Antipsychotic drugs should be avoided. (See <a class="local">'Benzodiazepine safety and administration'</a> below and  <a class="medical medical_review" href="/z/d/html/291.html" rel="external">"Assessment and emergency management of the acutely agitated or violent adult", section on 'Physical restraints'</a>.)</p><p></p><p class="headingAnchor" id="H13927951"><span class="h2">Underlying disorder</span><span class="headingEndMark"> — </span>Management of catatonia includes treating the underlying cause as soon as it is identified, which may improve outcomes [<a href="#rid9">9</a>]. On acute inpatient psychiatric units, catatonia is most likely to occur in bipolar disorder with psychotic features and psychotic depression [<a href="#rid10">10-13</a>]. Catatonia is also associated with psychotic disorders (eg, schizophrenia) and autism spectrum disorder [<a href="#rid5">5</a>]. Many general medical conditions can progress to catatonia, including infectious, metabolic, and neurologic disorders [<a href="#rid1">1,5,14</a>]. Treatment of the general medical condition may need to be prioritized over catatonia. (See  <a class="medical medical_review" href="/z/d/html/14683.html" rel="external">"Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis", section on 'Underlying disorders'</a>.)</p><p class="headingAnchor" id="H13927994"><span class="h3">Avoid dopamine blocking drugs</span><span class="headingEndMark"> — </span>Clinicians should try to avoid antipsychotics and other dopamine blocking drugs (eg, antiemetic agents) in patients with catatonia, including patients who are psychotic, impulsive, or aggressive [<a href="#rid1">1</a>]. First-generation antipsychotics do not appear to provide any benefit for treating catatonia [<a href="#rid15">15</a>]. Although there are reports that second-generation antipsychotics may treat catatonia [<a href="#rid2">2,16-19</a>], all antipsychotics can precipitate and worsen catatonia [<a href="#rid3">3,11,20</a>]. In addition, treating catatonia with an antipsychotic is a risk factor for the neuroleptic malignant syndrome (NMS) [<a href="#rid12">12,21-25</a>]; the risk may be particularly elevated in patients who are dehydrated, receive the antipsychotic parenterally or at rapidly escalating doses, or have a prior history of catatonia [<a href="#rid26">26</a>]. Antipsychotics are contraindicated in malignant catatonia. (See  <a class="medical medical_review" href="/z/d/html/14683.html" rel="external">"Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis", section on 'Malignant catatonia'</a>.)</p><p>After catatonia has resolved and the patient is autonomically stable, eating and drinking normally, and moving as expected, clinicians may consider resuming an antipsychotic drug to treat an underlying psychotic disorder [<a href="#rid12">12</a>]. However, reintroducing antipsychotics should be done cautiously, with patients examined regularly for autonomic instability and recurrence of catatonic signs. If a benzodiazepine resolved the catatonic episode, it should be maintained during treatment with an antipsychotic [<a href="#rid13">13</a>]. Although high-potency, first-generation antipsychotics carry the highest risk of NMS, all second-generation antipsychotics can also cause NMS [<a href="#rid24">24,27</a>]; one case report described NMS in a patient who was treated with low-dose <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> soon after recovering from catatonia [<a href="#rid28">28</a>].</p><p>NMS is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">"Neuroleptic malignant syndrome"</a>.)</p><p class="headingAnchor" id="H172176516"><span class="h2">Treatment algorithm</span><span class="headingEndMark"> — </span>First-line treatment for catatonia is a benzodiazepine or electroconvulsive therapy (ECT), depending upon the subtype of catatonia, clinical urgency, and availability of treatments  (<a class="graphic graphic_algorithm graphicRef111223" href="/z/d/graphic/111223.html" rel="external">algorithm 1</a>) [<a href="#rid1">1,15,29-33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with malignant catatonia, we recommend a benzodiazepine plus immediate preparation to administer ECT as soon as possible. If the benzodiazepine provides a substantive response during the first 24 to 48 hours, it can be continued in lieu of ECT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with nonmalignant catatonia, whether the behavioral phenotype (motor disturbance) is retarded or excited, we recommend treatment with a benzodiazepine (<a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> is used most often).</p><p></p><p>The goal of treatment is full remission.</p><p>Few randomized trials have evaluated benzodiazepines [<a href="#rid34">34</a>] or ECT [<a href="#rid35">35</a>] for acute catatonia, and these are limited to patients with nonaffective disorders. Multiple prospective open-label studies, cases series, and retrospective studies suggest that benzodiazepines alone, ECT alone, or benzodiazepines followed by ECT, lead to recovery in approximately 60 to 80 percent of patients [<a href="#rid1">1,15,26,36-39</a>]. Treatment guidelines from the American Psychiatric Association, United Kingdom National Institute for Health and Clinical Excellence, and World Federation of Societies of Biological Psychiatry recommend treating catatonia with either a benzodiazepine or ECT, depending upon the clinical urgency [<a href="#rid29">29-33</a>].</p><p>Multiple reviews of open-label studies, case series, and case reports have found that treatment of catatonia is the same regardless of the underlying disorder [<a href="#rid14">14,39,40</a>].</p><p>In children and adolescents, the approach to treatment is the same. In a prospective observational study of youth (n = 66, ages 9 to 19 years) who were hospitalized for catatonia, 51 patients received benzodiazepines, which were effective in 65 percent of cases [<a href="#rid40">40</a>]. The benzodiazepine used most often was <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> (mean dose 5 mg per day); the large majority received concomitant medications such as antipsychotics. A course of bilateral ECT was administered as first-line treatment in three patients, including two with malignant catatonia, and as second-line treatment in eight other patients.</p><p>Studies suggest that catatonia may respond to the combination of benzodiazepines plus ECT [<a href="#rid41">41</a>]. Although this is not our standard practice, when the combination is employed, an agent such as <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> is administered prior to ECT in order to reverse the anticonvulsant properties of benzodiazepines. (See  <a class="medical medical_review" href="/z/d/html/1709.html" rel="external">"Overview of electroconvulsive therapy (ECT) for adults", section on 'Psychotropic drugs'</a>.)</p><p class="headingAnchor" id="H85682819"><span class="h3">Malignant catatonia</span><span class="headingEndMark"> — </span>ECT is first-line treatment for patients with malignant catatonia  (<a class="graphic graphic_algorithm graphicRef111223" href="/z/d/graphic/111223.html" rel="external">algorithm 1</a>) [<a href="#rid1">1,15,29-33</a>]:</p><p>We recommend that clinicians concurrently start a benzodiazepine and the process of obtaining informed consent and medical consultation for ECT. If the patient does not measurably respond to a benzodiazepine within the first day or two, ECT should commence and the benzodiazepine should be discontinued. Reviews of case reports have found that mortality for progressive malignant catatonia increases if ECT does not begin within five days of symptom onset [<a href="#rid26">26,42</a>]. Another review of case reports found that in patients with malignant catatonia, response to ECT occurred in 9 of 11 patients (89 percent), whereas response to a benzodiazepine occurred in 2 of 5 patients (40 percent) [<a href="#rid15">15</a>].</p><p>For malignant catatonia that does not respond fully to initial treatment with ECT, we suggest continuing ECT until full remission is achieved. If improvement does not occur or plateaus at partial remission, we recommend continuing ECT and restarting the same benzodiazepine (eg, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>) that was used while preparations were made to initiate ECT. If there is no further incremental improvement after additional ECT (eg, three more treatments), clinicians should evaluate the quality of the ECT (eg, electrode placement and stimulus) and re-evaluate the patient to determine whether the diagnosis is malignant catatonia. If ECT has been administered properly and the diagnosis of malignant catatonia is confirmed, we suggest that treatment focus upon the underlying disorder (see <a class="local">'Underlying disorder'</a> above). As an example:</p><p class="bulletIndent1"><span class="glyph">●</span>Catatonia may be due to the neuroleptic malignant syndrome, which occurred in the context of administering a depot neuroleptic. Treatment consists of supportive care and watchful waiting while the neuroleptic is metabolized.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alternatively, catatonia may be secondary to mania; aggressive treatment of the manic syndrome should be pursued.</p><p></p><p>The safety and administration of benzodiazepines and ECT are discussed elsewhere in this topic. (See <a class="local">'Benzodiazepine safety and administration'</a> below and <a class="local">'Electroconvulsive therapy safety and administration'</a> below.)</p><p class="headingAnchor" id="H85682827"><span class="h3">Nonmalignant catatonia</span><span class="headingEndMark"> — </span>Based upon prospective open-label studies and case series, we recommend initial treatment with a benzodiazepine for patients with nonmalignant catatonia, whether the behavioral phenotype (motor disturbance) is retarded or excited  (<a class="graphic graphic_algorithm graphicRef111223" href="/z/d/graphic/111223.html" rel="external">algorithm 1</a>) [<a href="#rid1">1,15,29-33</a>]:</p><p><a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">Lorazepam</a> has been studied most frequently [<a href="#rid1">1,12,15,36,43,44</a>], but case reports also describe successful treatment with <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a>, <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a>, <a class="drug drug_general" data-topicid="9286" href="/z/d/drug information/9286.html" rel="external">clorazepate</a>, <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">midazolam</a>, and <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">alprazolam</a> [<a href="#rid45">45-54</a>]. In a review of case reports of 104 catatonic episodes that were treated with benzodiazepine monotherapy, 70 percent remitted; among the 72 episodes treated with lorazepam, 79 percent remitted [<a href="#rid15">15</a>]. Other reviews estimate that 60 to 80 percent of patients with catatonia respond to lorazepam monotherapy [<a href="#rid3">3,45,55</a>]. Although <a class="drug drug_general" data-topicid="8647" href="/z/d/drug information/8647.html" rel="external">amobarbital</a> was significantly more effective than placebo in a randomized trial [<a href="#rid56">56</a>], most authorities consider benzodiazepines as first-line pharmacotherapy because they are generally effective and safer than barbiturates [<a href="#rid1">1-3</a>]. In addition, benzodiazepines have been studied more often, are familiar to clinicians, and an antagonist (<a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a>) is available. (See <a class="local">'Benzodiazepine safety and administration'</a> below.)</p><p>Clinical factors may be associated with response to a benzodiazepine. Successful benzodiazepine treatment may be more likely in patients with a significant reduction of catatonic signs after the first dose of <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> or other benzodiazepine (positive lorazepam challenge test) [<a href="#rid42">42</a>]. Acutely catatonic patients with an underlying bipolar or depressive disorder may respond more favorably to a benzodiazepine than schizophrenic patients [<a href="#rid13">13,57</a>]. In addition, benzodiazepines at low doses do not appear to benefit chronic catatonia in schizophrenic patients. A randomized trial compared adjunctive lorazepam with placebo for treating slow-onset, long-standing (≥4 years) catatonic signs in severely disabled and treatment-resistant chronic schizophrenic patients; lorazepam 6 mg daily provided no benefit [<a href="#rid34">34</a>]. It is not clear whether a longer duration of catatonia prior to treatment is associated with a poorer response to treatment, due to contradictory study results [<a href="#rid13">13,36</a>]. Age, sex, and the number and pattern of catatonic signs do not appear to be associated with response to a benzodiazepine [<a href="#rid3">3,11,26,36</a>]. The lorazepam challenge test is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14683.html" rel="external">"Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis", section on 'Lorazepam challenge'</a>.)</p><p>Based upon clinical experience, retarded or excited catatonia generally responds to a benzodiazepine within one week. For patients who do not respond to a benzodiazepine within one week, ECT is the treatment of choice [<a href="#rid1">1,3,26,36</a>]. In addition, if the underlying cause of catatonia is a bipolar or depressive disorder, or for patients requiring a rapid treatment response, ECT is the most effective treatment option. Evidence supporting the use of ECT includes a small, three-week trial that enrolled inpatients (n = 14) with nonaffective catatonia who did not respond to <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> (6 to 8 mg/day) within five days; patients were randomly assigned to real ECT (bilateral) plus pill placebo or to sham ECT plus <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a> (4 to 6 mg/day) [<a href="#rid35">35</a>]. Improvement of catatonia was greater with real ECT than risperidone.</p><p>Based upon open-label studies, case series, and retrospective studies, it is estimated that approximately 60 percent or more of catatonic patients achieve remission with ECT, including patients unresponsive to a benzodiazepine [<a href="#rid3">3,29,36,37,43,58-60</a>]. As an example, a review of case reports of 55 catatonic episodes that were treated with ECT alone found that 85 percent remitted [<a href="#rid15">15</a>]. A subsequent chart review of 27 catatonic patients treated with ECT found that 59 percent improved [<a href="#rid37">37</a>]. For patients with a bipolar or depressive disorder or acute psychosis, ECT can relieve both the catatonic syndrome and the underlying psychopathology [<a href="#rid3">3,26</a>]. (See <a class="local">'Electroconvulsive therapy safety and administration'</a> below.)</p><p>There are no established predictors of response to ECT for patients with catatonia [<a href="#rid2">2</a>]. However, acutely catatonic patients with an underlying bipolar or depressive disorder may respond more favorably to ECT than schizophrenic patients [<a href="#rid57">57</a>], and ECT does not appear to benefit chronic catatonia in schizophrenic patients [<a href="#rid61">61</a>].</p><p>For retarded or excited catatonia that does not respond fully to initial treatment with a benzodiazepine and subsequent treatment with ECT, we suggest continuing ECT and restarting the same benzodiazepine (eg, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>) that was used initially. If there is no further incremental improvement after additional ECT (eg, three more treatments), clinicians should evaluate the quality of the ECT (eg, electrode placement and stimulus) and re-evaluate the patient to determine whether the diagnosis is retarded or excited catatonia. If ECT has been administered properly and the diagnosis of catatonia is confirmed, we suggest that treatment focus upon the underlying disorder (see <a class="local">'Underlying disorder'</a> above). In addition, it is reasonable to use other treatments that are described below. (See <a class="local">'Other treatments'</a> below.)</p><p class="headingAnchor" id="H6714262"><span class="h2">Benzodiazepine safety and administration</span><span class="headingEndMark"> — </span>Benzodiazepines are generally safe and well tolerated in this setting. At doses used for treating catatonia, benzodiazepines are not associated with respiratory depression in otherwise healthy adults. However, clinicians should be cognizant of concomitant drugs (eg, opioids) that can cause sedation or respiratory depression. In addition, benzodiazepines cause varying degrees of motor incoordination and increase the risk of falls [<a href="#rid12">12</a>].</p><p>Benzodiazepines can be administered intravenously, intramuscularly, or orally (<a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> is available in all three formulations) [<a href="#rid3">3,36</a>]. Intravenous administration is preferred to assure adherence and rapid, complete absorption (intravenous access also permits administration of fluids for dehydration). Intravenous benzodiazepines should be injected or infused slowly. As patients improve, they should be switched to oral medication.</p><p><a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">Lorazepam</a> has been studied most often, and is typically initiated at 1 to 2 mg three times per day. For patients who are already receiving lorazepam for another indication when they present with catatonia, the starting dose of lorazepam for catatonia (eg, 1 mg three times per day) is added to the existing dose of lorazepam (eg, 1 mg each night for insomnia). Close observation for a clinical response can substantiate the diagnosis of catatonia. (See  <a class="medical medical_review" href="/z/d/html/14683.html" rel="external">"Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis", section on 'Lorazepam challenge'</a>.)</p><p>Subsequently, the dose is increased by 3 mg per day every one to two days, depending upon patient response, tolerability, and clinical urgency. A dose of 6 to 21 mg daily is effective for most patients, but a dose of 30 mg per day is occasionally necessary [<a href="#rid1">1</a>]. For patients with excited catatonia, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> 1 to 2 mg is given at more frequent intervals until the patient is calm but awake.</p><p>A more cautious approach is suggested for patients at risk of cardiorespiratory compromise or oversedation, including patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular or respiratory disease</p><p class="bulletIndent1"><span class="glyph">●</span>Older age</p><p class="bulletIndent1"><span class="glyph">●</span>Obesity</p><p class="bulletIndent1"><span class="glyph">●</span>Volume depletion</p><p class="bulletIndent1"><span class="glyph">●</span>Prescriptions for opioid analgesics</p><p></p><p>For patients with these risk factors, the initial dose may be reduced to 0.5 mg three times per day and closer monitoring provided [<a href="#rid12">12,43</a>].</p><p>The duration of treatment required to achieve remission of catatonia with a benzodiazepine is typically 4 to 10 days [<a href="#rid42">42</a>]. However, in idiopathic recurrent catatonia, the benzodiazepine may need to be continued at the effective dose for three to six months to maintain recovery and then slowly tapered and discontinued; in some cases, longer maintenance treatment may be necessary [<a href="#rid62">62</a>].</p><p>Drug information topics are available for specific benzodiazepines.</p><p class="headingAnchor" id="H6714269"><span class="h2">Electroconvulsive therapy safety and administration</span><span class="headingEndMark"> — </span>ECT is generally safe, even in patients whose general medical status is compromised [<a href="#rid63">63</a>], as well as patients who are pregnant [<a href="#rid64">64</a>] or older (eg, ≥65 years) [<a href="#rid65">65</a>]. However, the success of ECT depends upon an appropriate pre-ECT evaluation, the goals of which are to optimize treatment efficacy and minimize the risk of cognitive and other side effects associated with ECT. ECT is typically administered with the same technique used for other indications. (See  <a class="medical medical_review" href="/z/d/html/4817.html" rel="external">"Medical evaluation for electroconvulsive therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1712.html" rel="external">"Technique for performing electroconvulsive therapy (ECT) in adults"</a>.)</p><p>There are no absolute contraindications to ECT [<a href="#rid66">66-70</a>]. Underlying general medical conditions may increase the risk of adverse effects of ECT or general anesthesia, but modern ECT technique and preprocedure consultation to optimize the patient’s general medical status reduce these risks. As an example, catatonic patients with motor immobility and muscle damage are at increased risk for transient hyperkalemia associated with the muscle relaxant <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a> [<a href="#rid2">2,14</a>]. This increased risk is eliminated by using a nondepolarizing muscle relaxant (eg, <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">rocuronium</a>) [<a href="#rid71">71</a>].</p><p>Electrode placement and other aspects of ECT technique for treating catatonia have not been standardized [<a href="#rid14">14</a>]. However, bitemporal electrode placement and brief pulse current are generally preferred [<a href="#rid1">1</a>]. ECT is generally given three times per week on alternating days. However, for patients with malignant catatonia, we suggest daily treatments until the patient is physiologically stable, which often occurs within two to five treatments [<a href="#rid1">1,72</a>]. At least six treatments are given regardless of the catatonia subtype to reduce the risk of sudden relapse. Most patients receiving ECT regardless of the indication remit with 6 to 12 treatments, but some patients may require 20 or more [<a href="#rid63">63</a>]. ECT is usually terminated after the acute catatonic episode has remitted, but one case report described maintenance ECT for a patient with recurrent catatonia [<a href="#rid73">73</a>]. Additional information about ECT is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1709.html" rel="external">"Overview of electroconvulsive therapy (ECT) for adults"</a> and  <a class="medical medical_review" href="/z/d/html/1712.html" rel="external">"Technique for performing electroconvulsive therapy (ECT) in adults"</a>.)</p><p>Case reports describe catatonic patients who responded to ECT plus <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> [<a href="#rid69">69,70</a>]. The decision to continue a benzodiazepine during ECT is determined by the patient’s initial response to the medication and the modifications in ECT technique that are required. For patients with a partial but incomplete response to lorazepam, the drug may be continued during ECT to maintain the drug’s therapeutic benefit. However, the benzodiazepine should be discontinued if it interferes with ECT (increases seizure threshold and shortens seizure duration) despite adjustments in the ECT technique. (See  <a class="medical medical_review" href="/z/d/html/1709.html" rel="external">"Overview of electroconvulsive therapy (ECT) for adults", section on 'Concurrent medications'</a>.)</p><p class="headingAnchor" id="H4932579"><span class="h2">Other treatments</span><span class="headingEndMark"> — </span>Alternative treatments may be available for patients with catatonia who do not respond to benzodiazepines and decline ECT or do not respond to ECT or have access to it [<a href="#rid3">3</a>]. Case reports describe other treatments that were added to an existing pharmacotherapy regimen and may possibly be beneficial. These other treatments include <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid74">74</a>], <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> [<a href="#rid75">75</a>], <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> [<a href="#rid76">76,77</a>], <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">zolpidem</a> [<a href="#rid3">3,78,79</a>], <a class="drug drug_general" data-topicid="10131" href="/z/d/drug information/10131.html" rel="external">memantine</a> [<a href="#rid80">80-83</a>], and <a class="drug drug_general" data-topicid="9164" href="/z/d/drug information/9164.html" rel="external">bromocriptine</a> [<a href="#rid84">84</a>]. <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">Amantadine</a> has also been used, but has dopamine agonist activity that can potentially worsen an underlying psychosis [<a href="#rid83">83</a>]. Additional case reports describe treatment of catatonia with repeated transcranial magnetic stimulation [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H6714290"><span class="h1">LONG-TERM PROGNOSIS</span><span class="headingEndMark"> — </span>Although the long-term outcome of catatonia has not been rigorously studied, catatonia appears to have a generally favorable prognosis, especially the retarded and excited subtypes [<a href="#rid3">3,85</a>]. Long-term prognosis appears to be linked to the nature and severity of the underlying psychiatric or general medical disorder [<a href="#rid2">2,26</a>]. Retarded or excited catatonia in patients with an underlying bipolar or depressive disorder or toxic-metabolic disorder usually resolves with treatment of the catatonic syndrome plus the underlying condition [<a href="#rid26">26</a>]. However, catatonia may persist for years, particularly in patients with schizophrenia [<a href="#rid34">34</a>]. In addition, patients with malignant catatonia may be left with permanent morbidity (eg, cognitive deficits, apathy syndromes, and limb strictures), and death rates of up to 20 percent have been reported [<a href="#rid42">42</a>].</p><p>Case reports describe recurrent catatonic episodes [<a href="#rid15">15,73</a>]. One case series of five patients reported that the mean interval between consecutive episodes was 11 months (range 5 to 20 months) [<a href="#rid86">86</a>]. The motor signs were generally consistent across each patient’s two episodes. For cases with complete information, the same treatment worked in the two episodes.</p><p class="headingAnchor" id="H2633051658"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116503.html" rel="external">"Society guideline links: Depressive disorders"</a>.)</p><p class="headingAnchor" id="H2451081"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition of catatonia</strong> – Catatonia is a behavioral syndrome marked by an inability to move normally despite full physical capacity to do so. The syndrome is associated with many psychiatric, neurologic, and general medical disorders. Signs of catatonia are listed in the tables  (<a class="graphic graphic_table graphicRef53391" href="/z/d/graphic/53391.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef66229" href="/z/d/graphic/66229.html" rel="external">table 2</a>). The three primary subtypes of catatonia are retarded, excited, and malignant. (See <a class="local">'Definition of catatonia'</a> above and  <a class="medical medical_review" href="/z/d/html/14683.html" rel="external">"Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment setting</strong> – Treatment of acute catatonia generally occurs in hospital settings where the patient’s general medical health can be monitored and optimized. Malignant catatonia in particular is life-threatening and generally warrants admission to an intensive care unit. (See <a class="local">'Setting and management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treating the underlying disorder</strong> – Concurrently treating the underlying psychiatric or general medical disorder along with the catatonia may improve outcomes. Clinicians should avoid using dopamine blocking drugs, even if patients are psychotic, impulsive, or aggressive. Treating catatonia with an antipsychotic is a risk factor for the neuroleptic malignant syndrome (NMS). Antipsychotics are contraindicated in malignant catatonia. (See <a class="local">'Underlying disorder'</a> above and <a class="local">'Avoid dopamine blocking drugs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treating malignant catatonia</strong> – Mortality in malignant catatonia may increase if electroconvulsive therapy (ECT) does not begin within five days of symptom onset. For patients with malignant catatonia, we recommend ECT rather than a benzodiazepine  (<a class="graphic graphic_algorithm graphicRef111223" href="/z/d/graphic/111223.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). A benzodiazepine should be administered during preparations for ECT; if malignant catatonia improves significantly with the benzodiazepine during the first 24 to 48 hours, it can be continued in lieu of ECT. (See <a class="local">'Treatment algorithm'</a> above and <a class="local">'Malignant catatonia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treating nonmalignant catatonia</strong> – For patients with nonmalignant catatonia, whether the behavioral phenotype (motor disturbance) is retarded or excited, we recommend a benzodiazepine rather than ECT (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). For retarded or excited catatonia that does not respond to a benzodiazepine, we suggest ECT rather than other medications (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Treatment algorithm'</a> above and <a class="local">'Nonmalignant catatonia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selecting and administering a benzodiazepine</strong> – The benzodiazepine used most often is intravenous <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> 1 to 2 mg three times per day, which is increased by 3 mg per day every one to two days. A dose of 6 to 21 mg daily is effective for most patients, but a dose of 30 mg per day is occasionally necessary. The benzodiazepine is usually continued orally at the effective dose for three to six months and then tapered and discontinued. Following remission of catatonia, the benzodiazepine should be continued if an antipsychotic drug is used to treat the underlying disorder. (See <a class="local">'Benzodiazepine safety and administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administering ECT</strong> – There are no absolute contraindications to ECT. For catatonic patients with motor immobility and muscle damage, a nondepolarizing muscle relaxant is used to eliminate the risk of transient hyperkalemia associated with the use of the <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a>. ECT is generally given three times per week on alternating days, but malignant catatonia may initially require daily treatments. ECT is typically administered at least six times with bilateral electrode placement and brief pulse current. (See <a class="local">'Electroconvulsive therapy safety and administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term prognosis</strong> – Retarded and excited catatonia both appear to have a generally favorable prognosis, especially in patients with an underlying bipolar or depressive disorder or toxic-metabolic disorder. By contrast, malignant catatonia may result in permanent morbidity, and death rates of up to 20 percent have been reported. (See <a class="local">'Long-term prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fink M, Taylor MA. The catatonia syndrome: forgotten but not gone. Arch Gen Psychiatry 2009; 66:1173.</a></li><li><a class="nounderline abstract_t">Zisselman MH, Jaffe RL. ECT in the treatment of a patient with catatonia: consent and complications. Am J Psychiatry 2010; 167:127.</a></li><li><a class="nounderline abstract_t">Francis A. Catatonia: diagnosis, classification, and treatment. Curr Psychiatry Rep 2010; 12:180.</a></li><li class="breakAll">The ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines. World Health Organization. http://www.who.int/classifications/icd/en/bluebook.pdf (Accessed on May 04, 2011).</li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision, American Psychiatric Association, Washington, D.C. 2022.</li><li class="breakAll">Mann SC, Caroff SN, Campbell EC, et al. Malignant catatonia. In: Current Clinical Neurology: Movement Disorder Emergencies: Diagnosis and Treatment, Frucht SI, Fahn S (Eds), Humana Press, Totowa, NJ 2005. p.53.</li><li><a class="nounderline abstract_t">Clinebell K, Azzam PN, Gopalan P, Haskett R. Guidelines for preventing common medical complications of catatonia: case report and literature review. J Clin Psychiatry 2014; 75:644.</a></li><li><a class="nounderline abstract_t">Ishida T, Sakurai H, Watanabe K, et al. Incidence of deep vein thrombosis in catatonic patients: A chart review. Psychiatry Res 2016; 241:61.</a></li><li><a class="nounderline abstract_t">Fink M, Taylor MA. Catatonia: subtype or syndrome in DSM? Am J Psychiatry 2006; 163:1875.</a></li><li><a class="nounderline abstract_t">Taylor MA, Abrams R. Catatonia. Prevalence and importance in the manic phase of manic-depressive illness. Arch Gen Psychiatry 1977; 34:1223.</a></li><li><a class="nounderline abstract_t">Taylor MA, Fink M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatry 2003; 160:1233.</a></li><li><a class="nounderline abstract_t">Rosebush PI, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry 1990; 51:357.</a></li><li><a class="nounderline abstract_t">Rosebush PI, Mazurek MF. Catatonia and its treatment. Schizophr Bull 2010; 36:239.</a></li><li><a class="nounderline abstract_t">Daniels J. Catatonia: clinical aspects and neurobiological correlates. J Neuropsychiatry Clin Neurosci 2009; 21:371.</a></li><li><a class="nounderline abstract_t">Hawkins JM, Archer KJ, Strakowski SM, Keck PE. Somatic treatment of catatonia. Int J Psychiatry Med 1995; 25:345.</a></li><li><a class="nounderline abstract_t">Martényi F, Metcalfe S, Schausberger B, Dossenbach MR. An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms. J Clin Psychiatry 2001; 62 Suppl 2:25.</a></li><li><a class="nounderline abstract_t">Angelopoulos EK, Corcondilas M, Kollias CT, et al. A case of catatonia successfully treated with ziprasidone, in a patient with DSM-IV delusional disorder. J Clin Psychopharmacol 2010; 30:745.</a></li><li><a class="nounderline abstract_t">Levy WO, Nunez CY. Use of ziprasidone to treat bipolar-associated catatonia. Bipolar Disord 2004; 6:166.</a></li><li><a class="nounderline abstract_t">Grenier E, Ryan M, Ko E, et al. Risperidone and lorazepam concomitant use in clonazepam refractory catatonia: a case report. J Nerv Ment Dis 2011; 199:987.</a></li><li><a class="nounderline abstract_t">Lee JW. Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome. J Clin Psychopharmacol 2010; 30:3.</a></li><li><a class="nounderline abstract_t">Carroll BT, Lee JW. Catatonia is a risk factor for neuroleptic malignant syndrome. J Clin Psychiatry 2004; 65:1722.</a></li><li><a class="nounderline abstract_t">Berardi D, Dell'Atti M, Amore M, et al. Clinical risk factors for neuroleptic malignant syndrome. Hum Psychopharmacol 2002; 17:99.</a></li><li><a class="nounderline abstract_t">White DA, Robins AH. Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry 1991; 158:419.</a></li><li><a class="nounderline abstract_t">Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164:870.</a></li><li><a class="nounderline abstract_t">White DA, Robins AH. An analysis of 17 catatonic patients diagnosed with neuroleptic malignant syndrome. CNS Spectr 2000; 5:58.</a></li><li class="breakAll">Freudenreich O, Nejad SH, Francis A, Fricchione GL. Psychosis, mania, and catatonia. In: Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL (Ed), American Psychiatric Publishing, Washington, DC 2011. p.219.</li><li><a class="nounderline abstract_t">Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009; 23:477.</a></li><li><a class="nounderline abstract_t">Paparrigopoulos T, Tzavellas E, Ferentinos P, et al. Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine. World J Biol Psychiatry 2009; 10:70.</a></li><li><a class="nounderline abstract_t">Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6:132.</a></li><li class="breakAll">American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia, Second Edition, 2004 http://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on May 10, 2011).</li><li class="breakAll">Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Institute for Health and Clinical Excellence clinical guideline 38, 2006 http://guidance.nice.org.uk/CG38 (Accessed on May 11, 2011).</li><li class="breakAll">American Psychiatric Association Practice Guideline for the Treatment of Patients With
Bipolar Disorder, Second Edition, 2002. http://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on May 11, 2011).</li><li class="breakAll">American Psychiatric Association Practice Guideline for the Treatment of Patients with
Major Depressive Disorder, Third Edition, 2010. http://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on May 11, 2011).</li><li><a class="nounderline abstract_t">Ungvari GS, Chiu HF, Chow LY, et al. Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study. Psychopharmacology (Berl) 1999; 142:393.</a></li><li><a class="nounderline abstract_t">Girish K, Gill NS. Electroconvulsive therapy in Lorazepam non-responsive catatonia. Indian J Psychiatry 2003; 45:21.</a></li><li><a class="nounderline abstract_t">Bush G, Fink M, Petrides G, et al. Catatonia. II. Treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand 1996; 93:137.</a></li><li><a class="nounderline abstract_t">van Waarde JA, Tuerlings JH, Verwey B, van der Mast RC. Electroconvulsive therapy for catatonia: treatment characteristics and outcomes in 27 patients. J ECT 2010; 26:248.</a></li><li><a class="nounderline abstract_t">Medda P, Toni C, Luchini F, et al. Catatonia in 26 patients with bipolar disorder: clinical features and response to electroconvulsive therapy. Bipolar Disord 2015; 17:892.</a></li><li><a class="nounderline abstract_t">Sienaert P, Dhossche DM, Vancampfort D, et al. A clinical review of the treatment of catatonia. Front Psychiatry 2014; 5:181.</a></li><li><a class="nounderline abstract_t">Raffin M, Zugaj-Bensaou L, Bodeau N, et al. Treatment use in a prospective naturalistic cohort of children and adolescents with catatonia. Eur Child Adolesc Psychiatry 2015; 24:441.</a></li><li><a class="nounderline abstract_t">Unal A, Bulbul F, Alpak G, et al. Effective treatment of catatonia by combination of benzodiazepine and electroconvulsive therapy. J ECT 2013; 29:206.</a></li><li class="breakAll">Fink M, Taylor MA. Catatonia: A Clinician's Guide to Diagnosis and Treatment, Cambridge University Press, Cambridge, UK 2003.</li><li><a class="nounderline abstract_t">Koek RJ, Mervis JR. Treatment-refractory catatonia, ECT, and parenteral lorazepam. Am J Psychiatry 1999; 156:160.</a></li><li><a class="nounderline abstract_t">Schmider J, Standhart H, Deuschle M, et al. A double-blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism. Biol Psychiatry 1999; 46:437.</a></li><li><a class="nounderline abstract_t">Fink M, Taylor MA. The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci 2001; 251 Suppl 1:I8.</a></li><li><a class="nounderline abstract_t">Hung YY, Huang TL. Lorazepam and diazepam for relieving catatonic features in multiple sclerosis. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1537.</a></li><li><a class="nounderline abstract_t">Tsai MC, Huang TL. Lorazepam and diazepam for relieving catatonic features precipitated by initial hemodialysis in a uremic patient: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:423.</a></li><li><a class="nounderline abstract_t">Hung YY, Huang TL. Lorazepam and diazepam rapidly relieve catatonic features in major depression. Clin Neuropharmacol 2006; 29:144.</a></li><li><a class="nounderline abstract_t">Huang TL. Lorazepam and diazepam rapidly relieve catatonic signs in patients with schizophrenia. Psychiatry Clin Neurosci 2005; 59:52.</a></li><li><a class="nounderline abstract_t">McEvoy JP, Lohr JB. Diazepam for catatonia. Am J Psychiatry 1984; 141:284.</a></li><li><a class="nounderline abstract_t">Delisle JD. Catatonia unexpectedly reversed by midazolam. Am J Psychiatry 1991; 148:809.</a></li><li><a class="nounderline abstract_t">Benazzi F. Parenteral clonazepam for catatonia. Can J Psychiatry 1991; 36:312.</a></li><li><a class="nounderline abstract_t">Kumar R. Acute severe catatonia in a young woman with chronic schizophrenia responding to parenteral clonazepam. Aust N Z J Psychiatry 2001; 35:391.</a></li><li><a class="nounderline abstract_t">Cottencin O, Warembourg F, de Chouly de Lenclave MB, et al. Catatonia and consultation-liaison psychiatry study of 12 cases. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1170.</a></li><li><a class="nounderline abstract_t">Northoff G. What catatonia can tell us about "top-down modulation": a neuropsychiatric hypothesis. Behav Brain Sci 2002; 25:555.</a></li><li><a class="nounderline abstract_t">McCall WV, Shelp FE, McDonald WM. Controlled investigation of the amobarbital interview for catatonic mutism. Am J Psychiatry 1992; 149:202.</a></li><li><a class="nounderline abstract_t">Ungvari GS, Caroff SN, Gerevich J. The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders. Schizophr Bull 2010; 36:231.</a></li><li><a class="nounderline abstract_t">Nisijima K, Ishiguro T. Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report of five cases. J ECT 1999; 15:158.</a></li><li><a class="nounderline abstract_t">Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 1999; 33:650.</a></li><li><a class="nounderline abstract_t">Ungvari GS, Leung CM, Wong MK, Lau J. Benzodiazepines in the treatment of catatonic syndrome. Acta Psychiatr Scand 1994; 89:285.</a></li><li><a class="nounderline abstract_t">Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 2005; :CD000076.</a></li><li><a class="nounderline abstract_t">Manjunatha N, Saddichha S, Khess CR. Idiopathic recurrent catatonia needs maintenance lorazepam: case report and review. Aust N Z J Psychiatry 2007; 41:625.</a></li><li class="breakAll">American Psychiatric Association Task Force on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, American Psychiatric Association, 2001.</li><li><a class="nounderline abstract_t">Pinna M, Manchia M, Pillai G, et al. Efficacy and safety of electroconvulsive therapy in the first trimester of pregnancy: a case of severe manic catatonia. Bipolar Disord 2015; 17:567.</a></li><li><a class="nounderline abstract_t">Wilkins KM, Ostroff R, Tampi RR. Efficacy of electroconvulsive therapy in the treatment of nondepressed psychiatric illness in elderly patients: a review of the literature. J Geriatr Psychiatry Neurol 2008; 21:3.</a></li><li><a class="nounderline abstract_t">Fam J, Lee TS, Lee HY, Ng BY. Electroconvulsive therapy for catatonia in neuropsychiatric systemic lupus erythematosus. J ECT 2010; 26:143.</a></li><li><a class="nounderline abstract_t">Gupta N, Pennell I, Hargovan H. Relief of catatonia associated with concurrent relief of sigmoid volvulus after electroconvulsive therapy. J ECT 2010; 26:134.</a></li><li><a class="nounderline abstract_t">Romanowicz M, Sola CL. Electroconvulsive therapy-responsive catatonia in a medically complicated patient. J ECT 2010; 26:234.</a></li><li><a class="nounderline abstract_t">Petrides G, Divadeenam KM, Bush G, Francis A. Synergism of lorazepam and electroconvulsive therapy in the treatment of catatonia. Biol Psychiatry 1997; 42:375.</a></li><li><a class="nounderline abstract_t">Espínola-Nadurille M, Ramírez-Bermúdez J, Fricchione GL. Pregnancy and malignant catatonia. Gen Hosp Psychiatry 2007; 29:69.</a></li><li><a class="nounderline abstract_t">Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology 2006; 104:158.</a></li><li><a class="nounderline abstract_t">Fink M, Kellner CH, McCall WV. Optimizing ECT Technique in Treating Catatonia. J ECT 2016; 32:149.</a></li><li><a class="nounderline abstract_t">Pontikes TK, Dinwiddie SH. Electroconvulsive therapy in a patient with multiple sclerosis and recurrent catatonia. J ECT 2010; 26:270.</a></li><li><a class="nounderline abstract_t">Kritzinger PR, Jordaan GP. Catatonia: an open prospective series with carbamazepine. Int J Neuropsychopharmacol 2001; 4:251.</a></li><li><a class="nounderline abstract_t">McDaniel WW, Spiegel DR, Sahota AK. Topiramate effect in catatonia: a case series. J Neuropsychiatry Clin Neurosci 2006; 18:234.</a></li><li><a class="nounderline abstract_t">Krüger S, Bräunig P. Intravenous valproic acid in the treatment of severe catatonia. J Neuropsychiatry Clin Neurosci 2001; 13:303.</a></li><li><a class="nounderline abstract_t">Yoshida I, Monji A, Hashioka S, et al. Prophylactic effect of valproate in the treatment for siblings with catatonia: a case report. J Clin Psychopharmacol 2005; 25:504.</a></li><li><a class="nounderline abstract_t">Zaw ZF, Bates GD. Replication of zolpidem test for catatonia in an adolescent. Lancet 1997; 349:1914.</a></li><li><a class="nounderline abstract_t">Thomas P, Rascle C, Mastain B, et al. Test for catatonia with zolpidem. Lancet 1997; 349:702.</a></li><li><a class="nounderline abstract_t">Carpenter SS, Hatchett AD, Fuller MA. Catatonic schizophrenia and the use of memantine. Ann Pharmacother 2006; 40:344.</a></li><li><a class="nounderline abstract_t">Thomas C, Carroll BT, Maley RT, et al. Memantine and catatonic schizophrenia. Am J Psychiatry 2005; 162:626.</a></li><li><a class="nounderline abstract_t">Munoz C, Yulan N, Achaval V, et al. Memantine in major depression with catatonic features. J Neuropsychiatry Clin Neurosci 2008; 20:119.</a></li><li><a class="nounderline abstract_t">Carroll BT, Goforth HW, Thomas C, et al. Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J Neuropsychiatry Clin Neurosci 2007; 19:406.</a></li><li><a class="nounderline abstract_t">Tang CP, Leung CM, Ungvari GS, Leung WK. The syndrome of lethal catatonia. Singapore Med J 1995; 36:400.</a></li><li><a class="nounderline abstract_t">Clark T, Rickards H. Catatonia. 2: Diagnosis, management and prognosis. Hosp Med 1999; 60:812.</a></li><li><a class="nounderline abstract_t">Francis A, Divadeenam KM, Bush G, Petrides G. Consistency of symptoms in recurrent catatonia. Compr Psychiatry 1997; 38:56.</a></li></ol></div><div id="topicVersionRevision">Topic 15869 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19884605" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The catatonia syndrome: forgotten but not gone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20123920" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : ECT in the treatment of a patient with catatonia: consent and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20425278" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Catatonia: diagnosis, classification, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20425278" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Catatonia: diagnosis, classification, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20425278" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Catatonia: diagnosis, classification, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20425278" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Catatonia: diagnosis, classification, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25004188" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Guidelines for preventing common medical complications of catatonia: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27156025" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Incidence of deep vein thrombosis in catatonic patients: A chart review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17074935" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Catatonia: subtype or syndrome in DSM?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/911221" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Catatonia. Prevalence and importance in the manic phase of manic-depressive illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12832234" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Catatonia in psychiatric classification: a home of its own.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2211547" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19969591" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Catatonia and its treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996245" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Catatonia: clinical aspects and neurobiological correlates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8822386" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Somatic treatment of catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11232748" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21057243" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A case of catatonia successfully treated with ziprasidone, in a patient with DSM-IV delusional disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15005757" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Use of ziprasidone to treat bipolar-associated catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22134459" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risperidone and lorazepam concomitant use in clonazepam refractory catatonia: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20075641" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15641881" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Catatonia is a risk factor for neuroleptic malignant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12404699" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical risk factors for neuroleptic malignant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1674666" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Catatonia: harbinger of the neuroleptic malignant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17541044" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neuroleptic malignant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18197157" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : An analysis of 17 catatonic patients diagnosed with neuroleptic malignant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18197157" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : An analysis of 17 catatonic patients diagnosed with neuroleptic malignant syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19480467" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19673089" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16173147" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16173147" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16173147" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16173147" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16173147" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10229064" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21206808" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Electroconvulsive therapy in Lorazepam non-responsive catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8686484" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Catatonia. II. Treatment with lorazepam and electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19935090" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Electroconvulsive therapy for catatonia: treatment characteristics and outcomes in 27 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26643014" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Catatonia in 26 patients with bipolar disorder: clinical features and response to electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25538636" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A clinical review of the treatment of catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25159089" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment use in a prospective naturalistic cohort of children and adolescents with catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23965606" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effective treatment of catatonia by combination of benzodiazepine and electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23965606" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effective treatment of catatonia by combination of benzodiazepine and electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9892323" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Treatment-refractory catatonia, ECT, and parenteral lorazepam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10435212" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A double-blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11776271" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The many varieties of catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17640789" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Lorazepam and diazepam for relieving catatonic features in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20026370" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Lorazepam and diazepam for relieving catatonic features precipitated by initial hemodialysis in a uremic patient: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16772813" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Lorazepam and diazepam rapidly relieve catatonic features in major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15679540" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Lorazepam and diazepam rapidly relieve catatonic signs in patients with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6691497" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Diazepam for catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1801768" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Catatonia unexpectedly reversed by midazolam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1868429" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Parenteral clonazepam for catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11437823" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Acute severe catatonia in a young woman with chronic schizophrenia responding to parenteral clonazepam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17537561" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Catatonia and consultation-liaison psychiatry study of 12 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12958742" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : What catatonia can tell us about "top-down modulation": a neuropsychiatric hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1734740" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Controlled investigation of the amobarbital interview for catatonic mutism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19776208" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10378156" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10544988" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8023696" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Benzodiazepines in the treatment of catatonic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846598" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Electroconvulsive therapy for schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17558626" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Idiopathic recurrent catatonia needs maintenance lorazepam: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17558626" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Idiopathic recurrent catatonia needs maintenance lorazepam: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25854818" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Efficacy and safety of electroconvulsive therapy in the first trimester of pregnancy: a case of severe manic catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18287164" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Efficacy of electroconvulsive therapy in the treatment of nondepressed psychiatric illness in elderly patients: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20514698" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Electroconvulsive therapy for catatonia in neuropsychiatric systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20514697" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Relief of catatonia associated with concurrent relief of sigmoid volvulus after electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19935089" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Electroconvulsive therapy-responsive catatonia in a medically complicated patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9276078" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Synergism of lorazepam and electroconvulsive therapy in the treatment of catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17189750" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pregnancy and malignant catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16394702" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27428478" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Optimizing ECT Technique in Treating Catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21155152" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Electroconvulsive therapy in a patient with multiple sclerosis and recurrent catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11602030" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Catatonia: an open prospective series with carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16720802" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Topiramate effect in catatonia: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11449040" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Intravenous valproic acid in the treatment of severe catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16160635" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Prophylactic effect of valproate in the treatment for siblings with catatonia: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9217783" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Replication of zolpidem test for catatonia in an adolescent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9078210" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Test for catatonia with zolpidem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16380435" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Catatonic schizophrenia and the use of memantine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741490" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Memantine and catatonic schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18305307" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Memantine in major depression with catatonic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18070843" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8919156" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The syndrome of lethal catatonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10707192" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Catatonia. 2: Diagnosis, management and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8980873" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Consistency of symptoms in recurrent catatonia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
